top of page
HOME
HOME
LEVERAGING AI AND DATA SCIENCE TO DRIVE ACCESS TO MEDICINES
We provide AI-powered data solutions that help unlock equitable access to medicines in five key European markets; France, Germany, Italy, Spain and the UK.

Our AI and analytics solutions provide unparalleled visibility of the access environment, helping pharma and healthcare organisations identify opportunities to improve access to life-changing innovations.
VB-logo-New-strap-2022-RGB-HEX-TRANS.png
Anchor 1

Why You're Here

WE MAXIMISE THE VALUE OF MEDICINES
ValueBase is driven by a singular mission: to ensure all patients have timely access to the best treatments available, no matter where they live.

We partner with pharma companies to visualise the access environment and highlight disparities in target therapy areas. Our AI-powered data solutions provide a unique evidence-base to inform strategies that maximise the value of medicines. 

The world’s biggest pharma companies use ValueBase as their data insights partner – helping them design agile access strategies that support every stage of the product lifecycle, from early asset to loss of exclusivity.


Together we’re unlocking equitable access to medicines. 
depositphotos_40759589-stock-photo-natural-female-eye.webp
We specialise in AI-powered data solutions that help pharma companies identify and manage barriers to access – allowing them to design strategies based on real-world indicators and meaningful analogues. We also partner with health providers and policymakers to highlight gaps in access that need addressing.

Our descriptive and predictive AI-led solutions can track the access environment in 
five key European markets – France, Germany, Italy, Spain and the UK – mapping the changes driving regional access in each country, across formularies, guidelines or contracts. Insights can be combined with your latest prescribing data to give you critical insights around availability and impact.

We can also
help you see into the future. Our AI solutions – powered by the highest quality longitudinal data out there – enable next generation predictive modelling, allowing companies to pre-empt (and plan for) negative access events with confidence. Now you really can predict the predictable and see the unseeable.
SEE THE UNSEEABLE

How We Help

Anchor 2
600x1920_EU.png

Our Solutions

THE COMPLETE PICTURE. ALL DAY, EVERY DAY
600x600_clear_v3.png
Our digital access tools provide the complete picture of availability, access and adoption of medicines in five key European markets. 

We monitor the market 24/7, allowing businesses to detect and respond to change as it happens or review trends over time. 

Our solutions empower brand teams with real-world intelligence that drives competitive advantage – and helps unlock equitable access to medicines. 
Anchor 6
Whre We Hep
Formulytics-ID-Primary-R-281022-RGB-HEX.png
Formulytics tracks medicines formularies all day, every day – detecting updates the day they happen.

It allows businesses to monitor product availability and adoption, benchmark competitors, identify early adopters and respond to gaps in access. Formulytics makes the invisible visible. Quickly and accurately.
VALUEBASE_Guidelight_FINAL LOGO PORT.png
In some countries, guidelines sit separately to formularies.
Guidelight can provide a real-time view of local guidelines. Once a therapy area is coded, it monitors the environment 24/7, capturing updates for every published guideline and every locality.

Our FOI system monitors updates to unpublished guidelines too, giving customers a 360° view of positioning, prescribing options and recommendations.
Our proprietary indexing tool, the Availability Index is a standard measure of access for every product that allows companies to compare the access availability of products within a locality and across regions.

It takes account of the initiating prescriber, the positioning and restrictions noted within the relevant access documents.
AI-RGB-HEX.png
IF IT’S A QUESTION OF ACCESS, WE'LL HELP YOU FIND THE ANSWERS
Pharma companies use ValueBase to answer the big questions. Our solutions track the access environment over time, unlocking rich datasets that inform decision-making at every stage of the product lifecycle.

In-market multidisciplinary teams rely on our data insights to support:
•  Commercial/brand strategy
•  Business development
•  Forecasting
•  Product launch
•  Strategy adjustment/refinement
  Loss of Exclusivity (LoE) planning

Click the buttons below to see some of the questions we can help you answer in 3 core areas:
FORECASTING
PRODUCT LAUNCH
LoE MANAGEMENT

Where We Help

Screens.png
600x1920.png

Use Cases

HOW WE ARE HELPING
ValueBase data solutions are helping companies transform their access strategies, driving access to medicines for patients across Europe. Here are just a few examples of hypotheses where we’ve helped.

Click the Use Cases below to find out what our customers learned.
Anchor 5

Our Tools

NEXT GENERATION ACCESS SOLUTIONS. ENGINEERED HERE.
ADA is our custom-designed artificial intelligence tool that works in the background of the business 24/7. ADA is programmed to look through millions of rows of UK formulary data and guidelines every day to flag changes for our data managers to investigate. Inspired by Ada Lovelace –who published the first known computer algorithm – she’s one of the team.

 
ADA-RGB.png
ANA_edited.jpg

ANA is ADA’s twin sister – her focus is on formularies in markets outside the UK.
Araneae-HORI-logo-R-OCT2022-RGB-HEX.jpg

Our web scraping system for extracting published data from formularies/access sources. Designed in-house by our data engineers.
Humanae-HORI-logo-R-OCT2022-RGB-HEX.jpg
Built in-house, Humanae is web resource monitoring software for formulary information.

How We Do It

DIGITAL INGENUITY WITH THE HUMAN TOUCH
Public information on formularies and guidelines is disparate, variable and hard to find. The volume of change each day is vast. If you want to monitor the environment, you need automation to remove the heavy lifting so humans can focus on the “smart things".

Our AI-led solutions combine smart data engineering with the human experience. Our systems are built in-house by our engineers using AI, machine learning and automation solutions to drive our innovations. Information is reviewed and cleansed by experts, then moved into data systems that fire our innovations.

It’s human experience and artificial intelligence combined to create insight that helps unlock access to medicines.
3812cfe5d066ea80e0227b8cc7923173_edited.
Anchor 7
Anchor 8
Anchor 9
VALUE STORIES
ValueBase Site Stories Background White.png
Access all areas: a short guide to formulary visibility
EXPLAINER
May 2024
ValueBase Site Stories Background Teal.png
NICE rejects Enhertu in breast cancer – but a NICE recommendation doesn’t guarantee access
BLOG
March 2024
ValueBase Site Stories Background White.png
"NHS not ready for new Alzheimer's drugs lecanemab and donanemab, warns charity"
OPINION
February 2024
ValueBase Site Stories Background Teal.png
VPAG is on the money – data is key to tackling unwarranted variation in adoption of medicines
ANALYSIS
February 2024
ValueBase Site Stories Background White.png
4 for 24: the trends that could shape access in 2024
BLOG
January 2024
ValueBase Site Stories Background Teal.png
Obesity & diabetes markets are growing – but launch strategies are variable
ANALYSIS
November 2023
ValueBase Site Stories Background White.png
CVD: are patients being denied access to life-changing medicines?
ANALYSIS
September 2023
ValueBase Site Stories Background Teal.png
Not NICE: why are women being deprived access to life-changing cancer treatments?
ANALYSIS
March 2023
ValueBase Site Stories Background White.png
Patients are being denied access to EAMS-listed medicines
ANALYSIS
February 2023
ValueBase Site Stories Background Teal.png
Has Postcode Prescribing got its own category on NHS formularies?
ANALYSIS
April 2023
ValueBase Site Stories Background White.png
NICE-recommended lung cancer treatments still absent from formularies
ANALYSIS
August 2023
ValueBase Site Stories Background Teal.png
Head and neck cancer patients missing out on life-extending treatment
ANALYSIS
July 2023
ValueBase Site Stories Background White.png
Endometrial cancer treatment granted EAMS status – but will patients get early access?
ANALYSIS
July 2023
ValueBase Site Stories Background Teal.png
Access to medicines consistently fails to meet mandatory targets in the UK
ANALYSIS
July 2023
ValueBase Site Stories Background White.png
PwC report exposes glaring disparities in UK healthcare
ANALYSIS
December 2022
ValueBase Site Stories Background Teal.png
Health inequity?
Let’s get it out of here
ANALYSIS
November 2022
ValueBase Site Stories Background White.png
FEATURE
NICE - but not enough. Why evidence is better than assumption when executing your access strategy
ValueBase Site Stories Background Teal.png
FEATURE
Mapping at launch:
Time to update the satnav 
ValueBase Site Stories Background White.png
VIDEO
Mastering the maze of UK formularies
Top Tips Final_edited_edited.jpg
ValueBase Site Stories Background Teal.png
FEATURE
Double your sales at launch? Here's how
ValueBase Site Stories Background White.png
ANALYSIS
A million patients with stroke, diabetes, asthma or kidney disease are missing out on approved medicines
ValueBase Site Stories Background Teal.png
VIDEO
Tracking formularies:
Five Top Tips

Our Values

PURPOSE-DRIVEN, VALUES-BASED
Why do we do it? That’s simple. We’re driven by a shared purpose:

To ensure medicines are available and accessible to all appropriate patients.

That’s your goal. It’s our goal too.

To achieve it, we adopt a values-based culture. Here are our values.
Anchor 10
Summerlytics_29June2022_FINAL_edited.jpg
Summerlytics_29June2022_4_edited.jpg
Client-centred, Patient-first
We take every opportunity to delight our customers – and
our customers’ customers
Equitable
We advocate equitable access to opportunities (and medicines)
Summerlytics_29June2022_1_edited.jpg
Summerlytics_29June2022_3_edited.jpg
Collaborative and Agile
We work together in highly effective cross-functional and agile teams
Supportive
We look out for each other. We’re compassionate, empathetic and respectful
Summerlytics_29June2022_2_edited.jpg
Flexible
We welcome and adapt to change and uncertainty
Summerlytics_29June2022_5_edited.jpg
Scalable
We engender a growth mindset
Anchor 11

OUR MANAGEMENT TEAM

Karen 2.png
Karen Westaway

Chief Executive Officer

Caroline.png
Caroline Shortland

Chief Operating Officer

Wilf.png
Wilf Iliffe

Director of Analytics

Paula.png
Paula Baxter

Commercial Excellence Director

Robyn 2.png
Robyn Nowers

Transformation Director

Chris 2.png
Chris Ross

Director of Content

VB Background.png

CONTACT US

To find out how you could bolster your access strategy using ValueBase’s tools and analytics – or arrange a demonstration – get in touch.

 

Simply drop us a note using the web form right here.

 

Email us on enquiries@thevaluebase.com

 

Or connect with us on LinkedIn

Thanks for submitting!

Anchor 12
bottom of page